Search results
Author(s):
Milind Y Desai
Added:
1 year ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Robert Anderson
Job title: Visiting Professorial Fellow
Author
Tarun W Dasari
Author
C Noel Bairey Merz
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Author(s):
Milind Y Desai
Added:
1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3…
View more
Author(s):
Milind Y Desai
Added:
10 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a…
View more
Brian Zenger
Research Area(s) / Expertise:
Author
Carlos Morillo
Author
Agnieszka Kotalczyk
Job title: Research Fellow
Author
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s):
Dung Viet Nguyen
,
Hoai Thi Thu Nguyen
Added:
9 months ago
Original Research